IGC Completes its Phase 1 Clinical Trial on Alzheimer’s Patients, Reports Safety and Tolerability

Rhea-AI Summary

India Globalization Capital (IGC) has completed its Phase 1 clinical trial of IGC-AD1, a cannabis-based investigational drug for Alzheimer’s disease. The trial involved 12 participants, primarily elderly individuals with mild to moderate Alzheimer’s. Results indicate that IGC-AD1 was safe and well-tolerated. Secondary endpoints have also been completed, but results are yet to be disclosed. IGC plans to seek FDA concurrence on these findings and aims for future trials to support potential relief for the projected 50 million Alzheimer’s patients worldwide by 2030.

Positive

• Completion of Phase 1 clinical trial for IGC-AD1.
• IGC-AD1 shown to be safe and well-tolerated among participants.
• First human trial using low doses of natural THC in Alzheimer's patients.

Negative

• Uncertain outcomes for secondary endpoints; results not disclosed.
• No assurance of favorable results from future trials or FDA approval.

POTOMAC, Md.--(BUSINESS WIRE)-- (NYSE American: IGC), India Globalization Capital, Inc. (“IGC”, or the “Company”), today announces the completion of its Phase 1 clinical trial on IGC’s cannabis-based investigational new drug, IGC-AD1, for patients suffering from Alzheimer’s disease. As previously disclosed, IGC submitted IGC-AD1 to the U.S. Food and Drug Administration (“FDA”) under Section 505(i) of the Federal Food, Drug, and Cosmetic Act. IGC received approval to proceed with the Phase 1 trial from the FDA on July 30, 2020.

The primary end point of this Phase 1 trial was safety and tolerability. Based on this study, and subject to FDA concurrence, generally, the cannabis-based investigational drug IGC-AD1 was safe and well-tolerated by the Alzheimer’s trial participants. The safety and tolerability data has been filed with the FDA in IGC’s Annual Report.

The trial was conducted on 12 participants suffering from Alzheimer’s disease. The participants represent a frail geriatric population with multiple comorbidities and mild to moderate Alzheimer’s disease. Each participant had a caregiver that helped manage the daily reporting. For this Phase 1 trial, the average age of participants was 80.9 years, with an average weight of 141.2 pounds with 66.7% being women and 33.3% being men.

The trial’s secondary end points, including pharmacokinetics, genotyping, neuropsychiatric inventory, and measurement of suicide severity have also been completed. We expect to report this data as it becomes available and after submission to the FDA. At this stage, there can be no assurance as to the results that this secondary data will show or that it will meet any of our expectations. ­­

To IGC’s knowledge, this is the first human clinical trial using low doses of natural Tetrahydrocannabinol (“THC”) in combination with another molecule, on Alzheimer’s patients. THC is a psychoactive member of the cannabinoid class of natural products produced by the Cannabis sativa plant. IGC hopes that, with future successful results from appropriate further trials subject to FDA approval, IGC-AD1 could contribute to relief for some of the 50 million people around the world expected to be impacted by Alzheimer's disease by 2030 (WHO, 2020).

About IGC:

India Globalization Capital, Inc. (IGC) engages in the development of cannabinoid-based therapies for indications such as Alzheimer's disease and pain. It operates in two lines of business, Infrastructure and Life Sciences and is headquartered in Potomac, MD.
www.igcinc.us, www.igcpharma.com, Twitter @IGCIR.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on IGC’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the investigational new drug or formulation described in this release, or failure to obtain FDA approval for the investigational new drug or additional clinical trials; testing results from human clinical trials that may not be favorable or as anticipated; general economic conditions that are less favorable than expected, including as a result of the ongoing COVID-19 pandemic; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC’s SEC filings. IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Reports on Form 10-K filed with the SEC on June 14, 2021, and Quarterly Report on Form 10-Q, filed with the SEC on August 11, 2020 as if fully incorporated and restated herein. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005938/en/

Claudia Grimaldi

info@igcinc.us/Phone: 301-983-0998

Source: India Globalization Capital, Inc.

FAQ

What are the results of the IGC-AD1 Phase 1 clinical trial?

The Phase 1 clinical trial demonstrated that IGC-AD1 was safe and well-tolerated among participants.

How many participants were involved in the IGC-AD1 clinical trial?

The trial involved 12 participants suffering from mild to moderate Alzheimer's disease.

What is the next step for IGC-AD1 after the Phase 1 trial?

IGC plans to submit the trial data to the FDA and seek approval for future trials.

What potential impact does IGC-AD1 have on Alzheimer's patients?

If successful in further trials, IGC-AD1 could provide relief for millions impacted by Alzheimer's disease.